Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 16, 2014The innovative devices allow pacemaker patients access to full body MRI scans in 1.5 Tesla and 3.0 Tesla systems
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the ACCOLADETM pacemaker family. When implanted with the company's INGEVITYTM leads, ACCOLADE pacemakers are the first...
-
Oct 9, 2014Comprehensive Clinical Data from Randomized Trials Reviewed
After reviewing updated data and analysis for the Boston Scientific Corporation (NYSE: BSX) WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device, the U.S. Food and Drug Administration (FDA)...
-
Oct 7, 2014La nuova tecnologia consente di affrontare patologie cardiache complesse che colpiscono in Europa 1,2 milioni di pazienti
I primi impianti, effettuati in questo periodo con la collaborazione di medici specialisti europei, hanno avuto risultati positivi e hanno consentito all’équipe medica di acquisire competenze...
-
Oct 2, 2014
Boston Scientific is leading the way in developing innovative cardiac rhythm management technologies, designed to improve health outcomes for patients suffering from arrhythmias. Just recently,...
-
Oct 2, 2014
Boston Scientific is leading the way in developing innovative cardiac rhythm management technologies, designed to improve health outcomes for patients suffering from arrhythmias. Just recently,...
-
Sep 29, 2014
New data for the Lotus™ Valve System announced at PCR London Valves 30-Day outcomes for the 250 patients enrolled in REPRISE II Extended Cohort trial were presented by Prof Ian Meredith at PCR...
-
Sep 29, 2014Neue Daten für das Lotus™-Klappensystem beim PCR London Valves Kongress vorgestellt
Prof. Ian Meredith hat im Rahmen des PCR London Valves Kongresses am Montag 30-Tage-Daten der REPRISE-II-Extension vorgestellt, die 250 Patienten einschließt. REPRISE II, eine Studie zur...
-
Sep 25, 2014Nuovi dati per la valvola Lotus™ presentati al congresso PCR London Valves
I dati a 30 giorni per i 250 pazienti arruolati nello studio di coorte esteso REPRISE II sono stati presentati il 29 settembre dal Professor Ian Meredith nell'ambito del congresso PCR London...
-
Sep 23, 2014Data From REPRISE III Clinical Trial Designed to Support U.S. Regulatory Approval
Boston Scientific Corporation (NYSE: BSX) has initiated the REPRISE III clinical trial, a pivotal study to evaluate the safety and effectiveness of the Lotus™ Valve System in patients with...
-
Sep 18, 2014Vercise DBS System is the First DBS System Offering Precise Neural Targeting and a 25-Year Battery Life
Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the Vercise™ Deep Brain Stimulation (DBS) System for the treatment of tremor, including the most common form of this movement...
-
Sep 17, 2014Vercise DBS System is the First DBS System Offering Precise Neural Targeting and a 25-Year Battery Life
Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the Vercise™ Deep Brain Stimulation (DBS) System for the treatment of tremor, including the most common form of this movement...
-
Sep 17, 2014Vercise DBS System is the First DBS System Offering Precise Neural Targeting and a 25-Year Battery Life
Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the Vercise™ Deep Brain Stimulation (DBS) System for the treatment of tremor, including the most common form of this movement...
-
Sep 17, 2014Vercise DBS System is the First DBS System Offering Precise Neural Targeting and a 25-Year Battery Life
Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the Vercise™ Deep Brain Stimulation (DBS) System for the treatment of tremor, including the most common form of this movement...
-
Sep 15, 2014Auch nach einem Jahr keine Fälle von moderater oder schwerer paravalvulärer Aorteninsuffizienz
Neue Daten aus dem klinischen Studienprogramm zum Lotus™-Klappensystem der Boston Scientific Corporation (NYSE: BSX) belegen weiterhin die gute Wirksamkeit und Einsatzmöglichkeit des Devices...
-
Aug 30, 2014
Boston Scientific has released the primary endpoint results from its NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) clinical trial, the first and only randomized sham-controlled clinical...
-
Aug 30, 2014Phase II feasibility trial provides first randomized sham-controlled data using vagus nerve stimulation to treat heart failure
Boston Scientific has released the primary endpoint results from its NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) clinical trial, the first and only randomized sham-controlled clinical...
-
Jul 11, 2014
Boston Scientific is leading the way in developing innovative cardiac rhythm management technologies, designed to improve health outcomes for patients suffering from arrhythmias. Just recently,...
-
Jun 26, 2014
Boston Scientific welcomes the National Institute for Health and Care Excellence (NICE) guidance on the use of implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy...
-
Jun 26, 2014
Boston Scientific welcomes the National Institute for Health and Care Excellence (NICE) guidance on the use of implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy...
-
Jun 26, 2014
Boston Scientific begrüßt die neuen Leitlinien des „National Institute for Health and Care Excellence“ (NICE) zum Einsatz von implantierbaren Kardioverter-Defibrillatoren (ICD) und Geräten...
-
Jun 14, 2014
Un video, resumen el congreso EuroPCR, que incluye los últimos resultados de los estudios clínicos EVOLVE y REPRISE II presentados por Dr. Kieth Oldroyd y Dr Daniel Blackman. Exención de...
-
Jun 14, 2014
Un breve video che racconta il congresso EuroPCR 2014, compresi gli ultimi dati clinici dagli studi EVOLVE e REPRISE II, presentati dal Dr. Keith G. Oldroyd e dal Dr. Daniel Blackman. ATTENZIONE:...
-
Jun 14, 2014
Un breve video che racconta il congresso EuroPCR 2014, compresi gli ultimi dati clinici dagli studi EVOLVE e REPRISE II, presentati dal Dr. Keith G. Oldroyd e dal Dr. Daniel Blackman.
-
Jun 13, 2014
In einer kurzen Video-Zusammenfassung zum EuroPCR-Kongress präsentieren Dr. Keith G. Oldroyd und Dr. Daniel Blackman die neuesten klinischen Daten der EVOLVE- und REPRISE-II-Studie....